Corbus Pharmaceu Stock Price, News & Analysis

Corbus Pharmaceuticals (NASDAQ: CRBP) announced its participation in the upcoming Piper Sandler 3rd Annual Virtual Obesity Symposium on June 26, 2025. CEO Yuval Cohen, Ph.D. will engage in a fireside chat at 10:00 a.m. ET, hosted by Biren Amin, Managing Director of Healthcare Equity Research at Piper Sandler.

The symposium will feature presentations from key opinion leaders and fireside chats with companies developing obesity therapeutics. The event is exclusively available to Piper Sandler clients through their representatives.

Corbus Pharmaceuticals (NASDAQ: CRBP) has announced that CEO Yuval Cohen will deliver a corporate presentation at the upcoming Jefferies Global Healthcare Conference in New York. The presentation is scheduled for June 4, 2025, at 4:55 p.m. ET. In addition to the presentation, Dr. Cohen will participate in one-on-one meetings with investors during the conference, which runs from June 3-5, 2025. A webcast of the presentation will be available for interested parties.

Corbus Pharmaceuticals (NASDAQ: CRBP) has appointed Rachelle Jacques as Chair of its Board of Directors, effective May 15, succeeding Alan Holmer who will remain on the Board. Jacques, who has served on Corbus' Board for over six years, brings more than 25 years of leadership experience across CEO, commercial, financial, and operational roles. The appointment comes at a crucial time as Corbus anticipates clinical readouts from all three drugs in its pipeline in the second half of 2025, including targeted oncology programs CRB-701 and CRB-601, and an obesity program.

Jacques' extensive experience includes serving as CEO of Akari Therapeutics and Enzyvant Therapeutics, where she achieved FDA approval for RETHYMIC®. She has also held executive positions at Alexion Pharmaceuticals, Baxalta, and Baxter International. Currently, she serves on the board of directors of uniQure N.V. and holds a bachelor's degree in business administration from Alma College.

Corbus Pharmaceuticals (NASDAQ: CRBP) has announced that CEO Yuval Cohen will participate in the 2025 RBC Capital Markets Global Healthcare Conference. The event will take place in New York from May 20-21, 2025. Dr. Cohen will engage in a fireside chat and one-on-one investor meetings on May 21 at 8:30 a.m. ET. The presentation will be available via webcast.

Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q1 2025 financial results and provided updates on its oncology and obesity pipeline. The company is advancing three key programs: CRB-701 (Nectin-4 ADC for solid tumors), CRB-913 (anti-obesity CB1 inverse agonist), and CRB-601 (anti-αvβ8 integrin mAB). CRB-701 showed promising Phase 1 data at ASCO GU, with clinical responses in urothelial, cervical, and head and neck cancers. The company reported a net loss of $17.0 million for Q1 2025, compared to $6.9 million in Q1 2024. Operating expenses increased to $19.8 million, primarily due to higher clinical development costs. Corbus maintains a strong financial position with $132.8 million in cash and investments, expected to fund operations through Q2 2027.

Corbus Pharmaceuticals (NASDAQ: CRBP) has initiated dosing in a Phase 1 clinical trial for CRB-913, their second-generation CB1 inverse agonist targeting obesity treatment. The drug represents an advancement over first-generation treatments like rimonabant, which were discontinued due to neuropsychiatric side effects.

Pre-clinical data from Obesity Week 2024 shows CRB-913 is significantly more peripherally restricted, with a brain-to-plasma ratio 50 times lower than rimonabant and 15 times more peripherally restricted than monlunabant. The single ascending dose/multiple ascending dose (SAD/MAD) trial is expected to complete in Q3 2025, followed by a Phase 1b dose-range finding study scheduled for completion in H2 2026.

The company envisions potential applications for CRB-913 as a monotherapy, in combination with incretin analogs, or as maintenance therapy following incretin analog treatment.

Corbus Pharmaceuticals (NASDAQ: CRBP) has reported its Q4 and full-year 2024 financial results, highlighting significant pipeline progress. The company's CRB-701 Nectin-4 targeting ADC showed promising results in Phase 1 Western study and received FDA Fast Track Designation for metastatic cervical cancer treatment.

Financial highlights include a Q4 2024 net loss of $9.5 million ($0.78 per share), compared to $8.0 million ($1.81 per share) in Q4 2023. Full-year 2024 net loss was $40.2 million ($3.68 per share), an improvement from $44.6 million in 2023. Operating expenses increased by $2.5 million to $12.6 million in Q4 2024.

The company maintains a strong financial position with $149.1 million in cash and investments as of December 31, 2024, providing runway through Q3 2027. Their obesity program CRB-913 is scheduled to begin human dosing in March 2025.

Corbus Pharmaceuticals (NASDAQ: CRBP) has announced that CEO Yuval Cohen will participate in five upcoming investor conferences during February and March 2025. The company will be featured at:

• B. Riley Securities Precision Oncology & Radiopharma Conference (Feb 28) - participating in a panel on Nectin-4 Targeting Therapies
• TD Cowen 45th Annual Health Care Conference (Mar 4) - delivering a presentation with webcast availability
• Wedbush Securities Cardiometabolic Conference (Mar 10) - joining a panel on alternative obesity targets beyond GLP1s
• Leerink Partners Global Healthcare Conference (Mar 12) - presenting with webcast access
• BMO 2025 Obesity Summit (Mar 25) - participating in an Emerging Technologies panel

These appearances highlight Corbus' strategic focus on both oncology and obesity/cardiometabolic therapeutic areas, providing investors multiple opportunities to engage with company leadership.

Corbus Pharmaceuticals (NASDAQ:CRBP) presented Phase 1 study results for CRB-701 (SYS6002), a next-generation Nectin-4 targeting ADC, at ASCO-GU 2025. The Western study, conducted in the US and UK, mirrored the four highest doses used in the China study and showed comparable safety and PK profiles with no dose-limiting toxicities.

Key findings include: low levels of peripheral neuropathy (4% combined rate), positive clinical responses in urothelial (mUC) and cervical cancer patients, and notably, multiple responses in head and neck squamous cell carcinoma (HNSCC). The Western study enrolled 38 participants across eight tumor types, with 26 evaluable for efficacy. Dose optimization is ongoing at 2.7 mg/kg and 3.6 mg/kg Q3W.

The drug demonstrated encouraging safety with mainly grade 1 or 2 adverse events, and showed efficacy even in tumors with low Nectin-4 expression levels.